GC Cell's earnings have been declining at an average annual rate of -82.1%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 1.2% per year.
How GC Cell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A144510 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
163,347
-257,977
20,569
18,083
31 Dec 25
165,523
-272,859
21,742
18,024
30 Sep 25
170,132
-98,193
21,262
23,176
30 Jun 25
170,465
-85,292
22,628
23,964
31 Mar 25
172,917
-82,244
23,926
24,356
31 Dec 24
174,451
-73,900
24,578
25,211
30 Sep 24
184,356
-3,388
26,785
23,796
30 Jun 24
184,444
-10,708
25,844
25,002
31 Mar 24
186,623
-6,802
24,353
25,045
31 Dec 23
187,544
-174
23,132
24,681
30 Sep 23
182,085
-10,813
23,641
27,611
30 Jun 23
186,192
-6,589
22,577
26,449
31 Mar 23
194,327
-946
23,635
27,279
31 Dec 22
236,120
26,537
23,284
26,426
30 Sep 22
262,621
51,819
22,393
23,260
30 Jun 22
251,382
52,690
21,601
21,514
31 Mar 22
224,848
50,939
16,598
19,388
31 Dec 21
168,310
31,422
12,618
18,490
30 Sep 21
121,231
15,404
6,681
17,282
30 Jun 21
106,810
8,733
3,786
16,564
31 Mar 21
97,619
9,518
3,187
14,795
31 Dec 20
85,562
4,160
2,808
13,961
30 Sep 20
75,083
2,256
2,954
12,672
30 Jun 20
65,762
599
2,808
13,698
31 Mar 20
60,762
-1,670
2,642
14,696
31 Dec 19
57,895
-2,276
2,354
15,110
30 Sep 19
55,920
-421
1,932
13,641
31 Dec 18
50,620
1,002
2,214
9,558
Quality Earnings: A144510 is currently unprofitable.
Growing Profit Margin: A144510 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A144510 is unprofitable, and losses have increased over the past 5 years at a rate of 82.1% per year.
Accelerating Growth: Unable to compare A144510's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A144510 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).
Return on Equity
High ROE: A144510 has a negative Return on Equity (-138.28%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/13 19:36
End of Day Share Price
2026/07/13 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GC Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.